HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Iterum Therapeutics PLC

Contributing Author

Recent Articles by Iterum Therapeutics PLC

Mar-27
Iterum Therapeutics Announces Filing of Winding Up Petition ITRM -79.77% GlobeNewswire
Feb-13
Iterum Therapeutics Provides Business Update ITRM -5.76% GlobeNewswire
Dec-23
Iterum Therapeutics Provides Business Update ITRM GlobeNewswire
Dec-17
Iterum Therapeutics Provides Business Update ITRM GlobeNewswire
Dec-05
Iterum Therapeutics Provides Business Update ITRM +7.27% GlobeNewswire
Nov-24
Iterum Therapeutics Provides Business Update ITRM +8.75% GlobeNewswire
Nov-14
Iterum Therapeutics Reports Third Quarter 2025 Financial Results ITRM -16.11% GlobeNewswire
Nov-07
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 ITRM GlobeNewswire
Oct-14
Iterum Therapeutics to Present Data at IDWeek 2025 ITRM GlobeNewswire
Sep-19
Iterum Therapeutics Provides Business Update ITRM GlobeNewswire
Aug-20
Iterum Therapeutics launches ORLYNVAH, the first and only oral penem antibiotic in the U.S. ITRM -8.56% GlobeNewswire
Aug-05
Iterum Therapeutics Reports Second Quarter 2025 Financial Results ITRM GlobeNewswire
Jul-29
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 ITRM GlobeNewswire
Jul-02
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ITRM GlobeNewswire
Jun-30
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH Launch and Commercial Growth ITRM GlobeNewswire
Jun-25
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence ITRM GlobeNewswire
Jun-11
Iterum Therapeutics Announces Partnership for Commercialization Services ITRM GlobeNewswire
May-19
Iterum Therapeutics Announces Extension of Term of Promissory Note ITRM GlobeNewswire
May-13
Iterum Therapeutics Reports First Quarter 2025 Financial Results ITRM -7.09% GlobeNewswire
May-06
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 ITRM -5.09% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)